

For nearly a century, countless doctors and medical researchers have pursued the now substantiated link between disease and morphological and molecular cell changes in patients.

As early as 1931 in Switzerland, Dr. Paul Niehan pioneered cell and organ-lysate therapies,

providing diseased organs with elements taken from identical healthy organs. In the last 50 years, Professor Karl Theurer of Germany furthered the work of Dr. Niehans, ultimately leading to the effective use of biological macromolecules.

More recently, advances in modern medicine and cell research have given birth to Cytoplasmatic Therapy. Distinct in nature from other organ-extract and cell-therapy techniques, Cytoplasmatic Therapy embraces an holistic approach to safely and effectively reverse cell defects. Patients are treated with relevant refined components extracted from healthy cells, thereby enabling diseased organs to again function properly.

Cytoplasmatic Therapy employs an internationally patented method for processing organ components endowed with immunological flexibility, thus making such treatment absolutely safe. The process was developed by Dr. Theurer, who recognised that the therapeutic efficacy of organ preparations must be linked to their molecular components: proteins, lipids, polysaccharides, nucleic acids and mediators of cellular energy. He perfected a chemical preparation of organ substances by acid-vapour lysis of lyophilised organ powder in a vacuum. The key to his patented method was the removal and reduction of type specificity while maintaining organ specificity and improving the solubility of cell components.